Colposcopy Referral and CIN3+Risk of Human Papillomavirus Genotyping Strategies in Cervical Cancer Screening

被引:2
|
作者
Kroon, Kelsi R. [1 ,2 ]
Bogaards, Johannes A. [1 ,2 ]
Heideman, Danielle A. M. [3 ,4 ,5 ]
Meijer, Chris J. L. M. [3 ,4 ]
Berkhof, Johannes [1 ,2 ]
机构
[1] Vrije Univ Amsterdam, Epidemiol & Data Sci, Amsterdam UMC, De Boelelaan 1089a, NL-1081 HV Amsterdam, Netherlands
[2] Amsterdam Publ Hlth Res Inst, Methodol, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Pathol, Amsterdam UMC, Amsterdam, Netherlands
[4] Canc Ctr Amsterdam, Imaging & Biomarkers, Amsterdam, Netherlands
[5] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands
基金
欧盟地平线“2020”;
关键词
RISK HUMAN-PAPILLOMAVIRUS; INTRAEPITHELIAL NEOPLASIA; BASE-LINE; CYTOLOGY; WOMEN; IMPLEMENTATION; GUIDELINES; POBASCAM;
D O I
10.1158/1055-9965.EPI-24-0046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: High-risk human papillomavirus (hrHPV)-based cervical cancer screening in the Netherlands led to a substantial increase in number of colposcopy referrals and low-grade lesions detected. Genotyping strategies may be employed to lower the screening-related burden.Methods: We evaluated 14 triage strategies with genotyping (HPV16/18 or HPV16/18/31/33/45/52/58) for hrHPV-positive borderlineormilddyskaryosis (BMD)ornormal cytology,usingdata from a population-based hrHPV-based screening trial with 5-year interval (POBASCAM). We considered colposcopy referral at baseline, after 6-month repeat cytology and after 5-year hrHPV testing. Performance was evaluated by one-round positive and negative predictive value (PPVandNPV) for CIN3+ and by two-roundcolposcopy referral rate. To identify efficient strategies, they were ordered by the one-round colposcopy referral rate. Adjacent strategies were compared by the marginal PPV for detecting one additional CIN3+ (mPPV).Results: The most conservative strategy (repeat cytology after BMD and HPV16/18/31/33/45/52/58-positive normal cytology, next round otherwise) yielded an mPPV of 28%, NPV of 98.2%, and two-round colposcopy referral rate of 47.2%. Adding direct referral after BMD or genotype-positive BMD yielded an mPPV <= 8.2%, NPV >= 98.5% and an increase in colposcopy referral rate of 1.9% to 6.5%. Adding direct referral after HPV16/18-positive normal cytology yielded an mPPV <= 3.5%, NPV >= 99.5% and an increase in colposcopy referral rate of 13.9%.Conclusions: Direct colposcopy referral of women with BMD or normal cytology is unlikely to be efficient, but genotype-guided direct referral after BMD may be considered because the increase in colposcopies is limited.Impact: hrHPV screening programs can become very efficient when immediate colposcopy referral is limited to women at highest CIN3+ risk. See related In the Spotlight, p. 979Impact: hrHPV screening programs can become very efficient when immediate colposcopy referral is limited to women at highest CIN3+ risk. See related In the Spotlight, p. 979
引用
收藏
页码:1037 / 1045
页数:9
相关论文
共 50 条
  • [11] Profile of MeltPro® HPV test for human papillomavirus genotyping and cervical precancer screening
    Liao, Yiqun
    Li, Qingge
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2019, 19 (10) : 857 - 862
  • [12] Cost Effectiveness of Human Papillomavirus-16/18 Genotyping in Cervical Cancer Screening
    Huh, Warner K.
    Williams, Erin
    Huang, Joice
    Bramley, Tommy
    Poulios, Nick
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2015, 13 (01) : 95 - 107
  • [13] Value of high-risk human papillomavirus detection combined with colposcopy in the diagnosis of cervical cancer and precancerous lesions
    Wang, Ping
    Gao, Dongxia
    Yu, Xiaoni
    Zhu, Gaoxiang
    ONCOLOGY LETTERS, 2024, 27 (04)
  • [14] Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era
    Tota, Joseph
    Mahmud, Salaheddin M.
    Ferenczy, Alex
    Coutlee, Francois
    Franco, Eduardo L.
    SEXUAL HEALTH, 2010, 7 (03) : 376 - 382
  • [15] Evaluation of portable colposcopy and human papillomavirus testing for screening of cervical cancer in rural China
    Newman, Haley
    Hu, Jilin
    Li, Xiao
    He, Jing
    Bradford, Leslie
    Shan, Songmei
    Wu, Xiaomei
    Zhu, Bin
    Yang, Wenyang
    Fu, Bingqin
    Zhu, Baosheng
    Gao, Guangping
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (01) : 23 - 27
  • [16] The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test
    Schiffman, Mark
    Boyle, Sean
    Raine-Bennett, Tina
    Katki, Hormuzd A.
    Gage, Julia C.
    Wentzensen, Nicolas
    Kornegay, Janet R.
    Apple, Raymond
    Aldrich, Carrie
    Erlich, Henry A.
    Tam, Thanh
    Befano, Brian
    Burk, Robert D.
    Castle, Philip E.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (09) : 1304 - 1310
  • [17] Cervical cancer screening: Impact of collection technique on human papillomavirus detection and genotyping
    Young, Alisa P.
    Olorunfemi, Mutiya
    Morrison, Leigh
    Kelley, Scott A.
    Laurie, Anna
    Mcevoy, Anna
    Schneiderhan, Jill
    Prussack, Julie
    O'Dwyer, Marie Claire
    Rockwell, Pamela
    Zazove, Philip
    Gabison, Jonathan
    Chargot, Jane
    Gallagher, Kristina
    Sen, Ananda
    Chen, Dongru
    Haro, Elizabeth A.
    Butcher, Emma A.
    Alves, Martha L.
    El Khoury, Christelle
    Dendrinos, Melinda L.
    Brashear, Nicole
    Smith, Roger
    Lieberman, Richard W.
    Saunders, Natalie
    Campbell, Elizabeth
    Walline, Heather M.
    Harper, Diane M.
    PREVENTIVE MEDICINE REPORTS, 2025, 50
  • [18] Modeling Cervical Cancer Screening Strategies With Varying Levels of Human Papillomavirus Vaccination
    Grimes, David Robert
    Corry, Edward M. A.
    Malagon, Talia
    O'Riain, Ciaran
    Franco, Eduardo L.
    Brennan, Donal J.
    JAMA NETWORK OPEN, 2021, 4 (06)
  • [19] Testing for Human Papillomavirus in Cervical Cancer Screening
    Ha Thanh Nishino
    Tambouret, Rosemary H.
    Wilbur, David C.
    CANCER CYTOPATHOLOGY, 2011, 119 (04) : 219 - 227
  • [20] Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended?
    Vink, Margaretha A.
    Bogaards, Johannes A.
    Meijer, Chris J. L. M.
    Berkhof, Johannes
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (02) : 420 - 427